ClinicalTrials.gg
Not yet recruitingNCT07850063Updated Nov 12, 2026

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

A Phase 3 interventional study of Survodutide and Placebo matching survodutide in Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease, sponsored by Boehringer Ingelheim. Not yet recruiting at 45 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Start date movedNewly registered+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Planned enrollment
4th of 22
600 · median 121
Started
2026
with 5 others
Phase 3
9 of 22
3 open now
Registered
19th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 4th largest by planned enrollment, is one of 6 that started in 2026, is one of 9 in phase 3, and was the 19th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is for adults aged 18 years and older who have a type of fatty liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD). People can take part if their body mass index (BMI) is 27 kg/m² or higher, and they have certain heart and blood vessel risk factors. The purpose of this study is to find out how a medicine called survodutide affects heart structure and function in people with MASLD.

Participants are put into 2 groups randomly, which means by chance. One group gets survodutide as an injection under the skin of the abdomen once a week. The other group gets placebo as an injection once a week. Placebo looks like survodutide but does not contain any medicine. The first injection is given at the study site. Later injections are usually given by the participants themselves at home using pre-filled syringes. Participants and doctors do not know who is getting survodutide or placebo.

Participants are in the study for up to 1.5 years. During this time, they visit the study site about 14 times and have about 4 phone calls with the study staff. At some of the visits, doctors use ultrasound scans to check the heart. The results are compared between the 2 groups to see if survodutide helps improve the health of the heart. The study staff also regularly check participants' health and take note of any health problems.

03

Conditions studied

  • Obesity
  • Metabolic Dysfunction-associated Steatotic Liver Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Age ≥18 years at the time of signing , and at least the legal age of consent in countries where it is >18 years
  2. Signed and dated written informed consent in accordance with international council for harmonisation - good clinical practice (ICH-GCP) and local legislation prior to admission to the trial
  3. (BMI) ≥27 kg/m²
  4. Hepatic steatosis established by imaging (ultrasound or cross sectional), transient elastography, or liver Further inclusion criteria apply.

Key exclusion criteria:

  1. Medications for obesity within 3 months before screening
  2. Known or suspected to the medicinal product (IMP) or related products
  3. Established diagnosis of heart failure or a known history of heart failure
  4. Impaired renal function at screening or requiring dialysis Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Survodutide arm

    Combination Product: Survodutide

  • Placebo comparator
    Placebo arm

    Combination Product: Placebo matching survodutide

Interventions

  • Combination productSurvodutide

    Survodutide

    Also known as: BI456906

  • Combination productPlacebo matching survodutide

    Placebo matching survodutide

06

What researchers measure

Primary outcomes

  1. Composite average Z-score (dimensionless) at Week 76 of cardiac structural and functional parameters

    Time frame: At week 76

Secondary outcomes

  1. Relative change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to 76 weeks (%)

    Time frame: At baseline and up to 76 weeks

  2. Relative change in alanine aminotransferase (ALT) from baseline to 76 weeks (%)

    Time frame: At baseline and up to 76 weeks

  3. Absolute change in KCCQ from baseline to 76 weeks (dimensionless)

    Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated, disease-specific participant-reported outcome measure designed to assess heart failure-related health status. The study will administer the KCCQ 23-item version. All scores range from 0 to 100, with higher scores indicating fewer symptoms and better health status.

    Time frame: At baseline and up to 76 weeks

  4. New use of oral loop diuretics during follow-up from baseline to 76 weeks, irrespective of symptoms (yes/no)

    Time frame: At baseline and up to 76 weeks

  5. Absolute change in systolic blood pressure (SBP) from baseline to 76 weeks (mmHg)

    Time frame: At baseline and up to 76 weeks

  6. Absolute change in fibrosis-4 index (FIB-4) from baseline (dimensionless)

    Time frame: At baseline and up to 76 weeks

  7. Absolute change in fatty liver index (FLI) from baseline to 76 weeks (dimensionless)

    Time frame: At baseline and up to 76 weeks

  8. Absolute change in hepatic steatosis index (HSI) from baseline to 76 weeks (dimensionless)

    Time frame: At baseline and up to 76 weeks

07

Study locations

45 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2029, 29 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 29 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Sep 30, 2026
StartEst.
Nov 18, 2026was Oct 2026
Primary completionEst.
Apr 29, 2029
CompletionEst.
Apr 29, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
34 sites added
Show 34 added (16 United States, 6 United Kingdom, 4 China, 4 Germany, 4 Spain)
  • California Liver Research Institute · Pasadena, United States
  • University of Kansas Medical Center · Kansas City, United States
  • Beth Israel Deaconess Medical Center · Boston, United States
  • Palmetto Clinical Research · Summerville, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC · Bristol, United States
  • Methodist Dallas Medical Center · Dallas, United States
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
  • Eugastro GmbH · Leipzig, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Mainz, Germany
  • Bradford Royal Infirmary · Bradford, United Kingdom
  • St James's University Hospital · Leeds, United Kingdom
  • St Bartholomew's Hospital · London, United Kingdom
  • Guy's Hospital · London, United Kingdom
  • Derriford Hospital · Plymouth, United Kingdom
  • Interventional Cardiology Medical Group · West Hills, United States
  • Piedmont HealthCare, PA · Statesville, United States
  • West China Hospital, Sichuan University · Chengdu, China
  • The Second Affiliated Hospital of Nanjing Medical University · Nanjing, China
  • Shanghai Tenth People's Hospital · Shanghai, China
  • Zentrum für Klinische Studien Bad Homburg · Bad Homburg, Germany
  • Universitätsklinikum Erlangen · Erlangen, Germany
  • Hospital Universitario Virgen de la Arrixaca · El Palmar, Spain
  • Hospital Virgen del Camino · Sanlúcar de Barrameda, Spain
  • Arizona Clinical Trials - Flagstaff Liver Clinic · Flagstaff, United States
  • Rocky Mountain Gastroenterology · Lakewood, United States
  • Florida Research Institute · Lakewood Rch, United States
  • Capital Digestive Care · Chevy Chase, United States
  • Woodholme Gastroenterology Associates · Glen Burnie, United States
  • Huron Gastroenterology Associates · Ypsilanti, United States
  • Moses H. Cone Memorial Hospital · Greensboro, United States
  • …and 4 more on the registry record
across 3 updates, Oct 16, 2026 – Nov 12, 2026
Start date
Oct 23, 2026→Nov 18, 2026
moved 2 times, Oct 30, 2026 – Nov 12, 2026
Site contacts
Changed at 7 sites. See the sites
Show 7 sites
  • The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, United StatesContact •••2368→•••2368
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact •••2368→•••2368
  • Fomat Medical Research · Oxnard, United StatesContact •••2368→•••2368
  • Covenant Metabolic Specialists, LLC - University Park · University Park, United StatesContact •••2368→•••2368
  • Kansas Medical Clinic PA · Topeka, United StatesContact •••2368→•••2368
  • Southwest Gastroenterology Associates, P.C. · Albuquerque, United StatesContact •••2368→•••2368
  • Duke University Medical Center · Durham, United StatesContact •••2368→•••2368
Oct 16, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 4 updates
  1. Nov 12, 2026
    11 sites added
    Show 11 added (8 United States, 2 Spain, 1 United Kingdom)
    • Arizona Clinical Trials - Flagstaff Liver Clinic · Flagstaff, United States
    • Rocky Mountain Gastroenterology · Lakewood, United States
    • Florida Research Institute · Lakewood Rch, United States
    • Capital Digestive Care · Chevy Chase, United States
    • Woodholme Gastroenterology Associates · Glen Burnie, United States
    • Huron Gastroenterology Associates · Ypsilanti, United States
    • Moses H. Cone Memorial Hospital · Greensboro, United States
    • Oregon Health & Sciences University · Portland, United States
    • Hospital Quironsalud Barcelona · Barcelona, Spain
    • Hospital General Universitario Gregorio Marañón · Madrid, Spain
    • Musgrove Park Hospital · Taunton, United Kingdom
    Start date Nov 2, 2026→Nov 18, 2026
    + 1 other change: verification date
  2. Oct 30, 2026
    9 sites added
    Show 9 added (3 China, 2 United States, 2 Germany, 2 Spain)
    • Interventional Cardiology Medical Group · West Hills, United States
    • Piedmont HealthCare, PA · Statesville, United States
    • West China Hospital, Sichuan University · Chengdu, China
    • The Second Affiliated Hospital of Nanjing Medical University · Nanjing, China
    • Shanghai Tenth People's Hospital · Shanghai, China
    • Zentrum für Klinische Studien Bad Homburg · Bad Homburg, Germany
    • Universitätsklinikum Erlangen · Erlangen, Germany
    • Hospital Universitario Virgen de la Arrixaca · El Palmar, Spain
    • Hospital Virgen del Camino · Sanlúcar de Barrameda, Spain
    Start date Oct 23, 2026→Nov 2, 2026
  3. Oct 16, 2026
    14 sites added
    Show 14 added (6 United States, 5 United Kingdom, 2 Germany, 1 China)
    • California Liver Research Institute · Pasadena, United States
    • University of Kansas Medical Center · Kansas City, United States
    • Beth Israel Deaconess Medical Center · Boston, United States
    • Palmetto Clinical Research · Summerville, United States
    • Internal Medicine and Pediatric Associates of Bristol, PC · Bristol, United States
    • Methodist Dallas Medical Center · Dallas, United States
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    • Eugastro GmbH · Leipzig, Germany
    • Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Mainz, Germany
    • Bradford Royal Infirmary · Bradford, United Kingdom
    • St James's University Hospital · Leeds, United Kingdom
    • St Bartholomew's Hospital · London, United Kingdom
    • Guy's Hospital · London, United Kingdom
    • Derriford Hospital · Plymouth, United Kingdom
    Site contacts Changed at 7 sites. See the sites
    Show 7 sites
    • The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, United StatesContact •••2368→•••2368
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact •••2368→•••2368
    • Fomat Medical Research · Oxnard, United StatesContact •••2368→•••2368
    • Covenant Metabolic Specialists, LLC - University Park · University Park, United StatesContact •••2368→•••2368
    • Kansas Medical Clinic PA · Topeka, United StatesContact •••2368→•••2368
    • Southwest Gastroenterology Associates, P.C. · Albuquerque, United StatesContact •••2368→•••2368
    • Duke University Medical Center · Durham, United StatesContact •••2368→•••2368
    + 1 other change: verification date
  4. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850063
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Nov 18, 2026 (estimated)
Primary completion
Apr 29, 2029 (estimated)
Completion
Apr 29, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
18002430127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion